ImmunityBio, Inc.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS15
PHASE 3 / 2-32
RECRUITING6
READOUTS ≤12 MONTHS4
READOUT SLIPPED >6 MO58%
Delay Index: of 12 active trials registered more than a year ago, 7 have moved their primary completion (readout) date by more than 6 months since first registration (median +8.0 months). See all sponsors →
Open ImmunityBio, Inc. on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| N-803 and BCG NCT03022825 |
P2/3 | Active, not recruiting | Bladder Cancer | 190 | 2024-10-01 (+70 mo) |
| N-803 NCT04390399 |
P2 | Active, not recruiting | Pancreatic Cancer | 328 | 2025-10-13 (+29 mo) |
| BCG (50mg/instillation) + N-803 (400 μg/instillation) NCT02138734 |
P1/2 | Active, not recruiting | Non-muscle Invasive Bladder Cancer | 369 | 2026-09-30 (+101 mo) |
| INTERRUPT_LC NCT07108036 |
P2 | Recruiting | Long COVID | 20 | 2026-10 (+2 mo) |
| N-803 and BCG NCT06829823 |
P2 | Not yet recruiting | Non-muscle Invasive Bladder Cancer (NMIBC) | 20 | 2026-11 (+6 mo) |
| Anktiva NCT07123727 |
P2 | Recruiting | Long COVID; Long COVID Syndrome | 40 | 2027-03 (+8 mo) |
| Gemcitabine NCT06710288 |
P2 | Recruiting | Platinum-resistant Ovarian Cancer | 20 | 2027-05 |
| CD19 t-haNK- IV Administration NCT07125872 |
P2 | Recruiting | Relapsed B-Cell Non Hodgkin Lymphoma | 20 | 2027-05-25 |
| CD19 t-haNK- IV Administration NCT07477366 |
P2 | Not yet recruiting | Relapsed B-Cell Non-Hodgkin Lymphoma | 20 | 2027-12 |
| Intravesical Recombinant Mycobacterium (rMBCG) NCT06800963 |
P1/2 | Recruiting | NMIBC | 40 | 2028-02 |
| Nogapendekin alfa inbakicept (NAI) NCT07783789 |
P2 | Not yet recruiting | Sepsis | 50 | 2028-05-12 |
| N-803 NCT06745908 |
P3 | Recruiting | NSCLC Stage IV | 507 | 2028-09 |
| N-803 + Pembrolizumab NCT03228667 |
P2 | Active, not recruiting | Non-Small Cell Lung Cancer; Small Cell Lung Cancer | 40 | 2029-08-31 (+108 mo) |
| Bevacizumab NCT06061809 |
P2 | Active, not recruiting | Glioblastoma | 34 | 2029-12-31 (+12 mo) |
| Nogapendekin Alfa Inbakicept (NAI) NCT07628062 |
P2 | Not yet recruiting | HPV-Positive Oropharyngeal Squamous Cell Carcinoma; Oropharyngeal Squamous Cell Carcinoma | 70 | 2030-12-31 |